Study On Hepatitis B Surface Antigen In Transgenic Ginseng Cell Line

Hepatitis B virus infection is one of the most widespread viralinfections of human, especially in China. The hepatitis B virus (HBV),discovered in 1966, infects more than 350 million people worldwide.Hepatitis B is a leading cause of chronic hepatitis, cirrhosis, andhepatocellular carcinoma, accounting for 1 million deaths annually.Knowledge of the intricacies of viral infection and of the molecular biologyof this fascinating virus has led to the successful development of a vaccineand to treatment sometimes capable of eradicating chronic infection.The existing vaccine to prevent HBV infection is a biotechnologyproduct that falls in the category of ''subunit vaccines''.CurrentlyHBsAg is manufactured commercially using both yeast and mammaliancultures and was the first licensed recombinantly manufactured subunitvaccine, replacing human serum-derived formulations. To find anequivalent or improved vaccine that will serve poorer countries of the world,where the HBV disease burden remains at epidemic levels, and vaccinecosts preclude the use of the currently available product, we pursue to anplant-derived vaccine against HBV infection. Plant cells provide a cheaperalternative to other cells because media requirements are only nutrients,salts, vitamins, and growth regulators .They can be grown in conventionalfermenters with minor adjustments in batch, fed batch, perfusion, andcontinuous fermentation modes.Our team has get some advance in Hepatitis B Surface Antigen inTransgenic Ginseng Cell Line. HBsAg-s gene was obtained from C28 cellcontaining the HBsAg-s DNA fragment using PCR and formed binary plantvector pBIBS. Agrobacterium tumefaciens carrying pBIBS was used to...